Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
Authors:
- S IkedaSIS Ikeda
- H ChisuwaHCH Chisuwa
- S KawasakiSKS Kawasaki
- J OzawaJOJ Ozawa
- Y HoshiiYHY Hoshii
- T YokotaTYT Yokota
- T AoiTAT Aoi
Open Access
- 1 November 1997
- journal article
- case report
- Published by BMJ in Journal of Clinical Pathology
- Vol. 50 (11) , 965-967
Abstract
A case is reported of a 21 year old woman who suffered from Castleman's disease and systemic reactive amyloidosis. The serum concentrations of serum amyloid A (SAA) and interleukin 6 (IL-6) were extremely high and amyloid protein was immunohistochemically identified as AA. After surgical excision of a large retroperitoneal lymph node with the pathological findings of plasma cell type of Castleman's disease, both serum SAA and IL-6 declined, showing a similar pattern of reduction curves. All clinical symptoms and laboratory abnormalities greatly improved. The biochemical feature of Castleman's disease is abnormal production of IL-6 and this cytokine continuously may stimulate the synthesis of an amyloid precursor, SAA, causing systemic reactive (AA) amyloidosis. This pathogenetic theory is strongly supported by the present study.Keywords
This publication has 11 references indexed in Scilit:
- The acute phase protein response in patients receiving subcutaneous IL-6Clinical and Experimental Immunology, 1995
- Castleman Disease and Renal AmyloidosisAnnals of Internal Medicine, 1995
- Reversal of nephrotic syndrome due to reactive amyloidosis (AA‐type) after excision of localized Castleman's diseaseAmerican Journal of Hematology, 1994
- Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 AntibodyNew England Journal of Medicine, 1994
- Secondary (AA) Amyloidosis Associated With Castleman’s Disease:Report of Two Cases and Review of the LiteratureAmerican Journal of Clinical Pathology, 1993
- PATHOGENIC SIGNIFICANCE OF INTERLEUKIN-6 (IL-6/BSF-2) IN CASTLEMANS DISEASE1989
- Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's diseaseBlood, 1989
- Recombinant human interleukin‐6 (IL‐6/BSF‐2/HSF) regulates the synthesis of acute phase proteins in human hepatocytesFEBS Letters, 1988
- A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.Journal of Clinical Oncology, 1985
- Giant lymph node hyperplasia with unusual clinicopathologic featuresCancer, 1984